<DOC>
	<DOCNO>NCT01911156</DOCNO>
	<brief_summary>This prospective randomized , open-label , phase IV clinical trial learn effect , good and/or bad , discontinue continue nucleos ( ) ide analogue ( NA ) treatment 72 week participant chronic hepatitis B infection whose immune system control amount virus level blood least 12 month NA therapy . About 66 adult men woman participate study University Health Network include Toronto Western Hospital 72 week .</brief_summary>
	<brief_title>Sustained Off-treatment Response After HBeAg Loss Chronic Hepatitis B Patients Treated With Nucleos ( ) Ide Analogues</brief_title>
	<detailed_description>Chronic infection hepatitis B virus ( HBV ) prevalent world-wide ( estimate affect 360 million individual ) . Chronic hepatitis b may result progressive liver disease lead cirrhosis , end-stage liver disease hepatocellular carcinoma ( HCC ) . Chronic hepatitis B also benign non-progressive , evolve inactive carrier state rarely lead significant liver injury HCC . Over last year , several highly effective antiviral agent develop approve use treatment chronic hepatitis B . Current therapy chronic hepatitis B ( CHB ) aim stop progression cirrhosis hepatocellular carcinoma . This prospective randomized , open-label , phase IV clinical trial learn effect , good and/or bad , discontinue continue NA treatment 72 week participant chronic hepatitis B infection whose immune system control amount virus level blood least 12 month NA therapy . About 66 adult men woman participate study University Health Network include Toronto Western Hospital 72 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Chronic hepatitis B ( HBsAg positive &gt; 6 month ) Currently NA monotherapy ≥1 year prior screen HBeAg negative antiHBe antibody HBV DNA undetectable least 12 month prior screen screen ( HBV DNA assay low limit quantification least 50 IU/mL ) Documented HBeAg positive start NA monotherapy Age &gt; 18 year Written inform consent Treatment investigational drug within 30 day screen Severe hepatitis activity document ALT &gt; 10x ULN Creatinine clearance &lt; 70 ml/min Presence cirrhosis document biopsy within 5 year , fibroscan &gt; 9kPa , fibrotest &gt; 0.48 Preexistent neutropenia ( neutrophils ≤1,000/mm3 ) Coinfection hepatitis C virus and/or human immunodeficiency virus ( HIV ) Other acquire inherited cause liver disease Alpha fetoprotein &gt; 50 ng/ml Hyper hypothyroidism Immune suppressive treatment within previous 6 month Pregnancy , lactation Other significant medical illness might interfere study Any medical condition requiring , likely require chronic systemic administration steroid , course study Substance abuse ( alcohol ( ≥80 g/day ) inhale drug ( past 2 year ) Any condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>